MethyPatch Noven

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1222-1224

  Sane, Natasha ^a   McGough, James J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MARKETING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; METHYLPHENIDATE;

EID: 0036707270     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. 325808 Noven developing transdermal methylphenidate patch for attention deficit hyperactivity disorder. Noven Pharmaceuticals Inc Press Release 1999 May 25
2. 358106 Noven completes successful phase II study of once-a-day transdermal methylphenidate patch - Phase III studies for MethylPatch to begin in summer 2000; New patch may eliminate broad social issues presented by AD/HD pill therapies. Noven Pharmaceuticals Inc Press Release 2002 March 02
3. 388188 Noven announces record financial results: Net income up 193% over 1999 third quarter quarterly revenues increase 38% over prior year period. Noven Pharmaceuticals Inc Press Release 2000 November 01
4. 400122 Noven announces record financial results. Noven Pharmaceuticals Inc Press Release 2001 February 26
5. 403771 Noven delays filing of new drug application for transdermal methylphenidate system. Noven Pharmaceuticals Inc Press Release 2001 April 02 Press release indicating that a supplemental study was needed after the initial phase III study of MethyPatch concluded.
6. 407254 Noven announces record financial results. Noven Pharmaceuticals Inc Press Release 2000 February 26
7. 407640 Noven announces first quarter 2001 financial results: Pre-tax income increases 126% - Vivelle family market share increases to nearly 30%. Noven Pharmaceuticals Inc Press Release 2001 April 30
8. 410285 Noven issued US potent for transdermal methylphenidate. Noven Pharmaceuticals Inc Press Release 2001 May 23
9. 417877 Noven announces second quarter financial results. Noven Pharmaceuticals Inc Press Release 2001 August 02
10. 422762 Shire Pharmaceuticals - No thoroughbred. Merrill Lynch Capital Markets 2001 June 01
11. 427321 Phase III trial for Noven's MethyPatch underway: MethyPatch clinical data presented at AACAP meeting. Noven Pharmaceuticals Inc Press Release 2001 October 29
12. 438893 Noven completes patient enrollment for MethyPatch phase III clinical trial. Noven Pharmaceuticals Inc Press Release 2001 February 07
13. 441478 Noven reports 2001 earnings per share of $0.51. Noven Pharamceuticals Inc Press Release 2001 February 26
14. 445181 Noven announces success of phase III study for once-daily MethyPatch. Noven Pharmaceuticals Inc Press Release 2002 April 01
15. 452505 Stimulant medications. Greenhill LL, Halperin JM, Abikoff H J Am Aad Child Adolesc Psychiatry 1999 38 5 503-512. Review article on the safety and efficacy of stimulants in the treatment of ADHD.
16. 452643 Developments in Transdermal Technology. Noven Pharmaceuticals Inc Internet Site www.Noven.com/Novendoc8.pdf. Information on Noven's patended transdermal delivery system from their company website.
17. 452644 Product information. Noven Pharmaceuticals Inc Internet Site www.noven.com/products/com 2002 May 27
18. 452646 Efficacy of once-daily transdermal methylphenidate in children with ADHD. Pelham WE Jr, Manos MJ, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN Internet Site www.noven.com/research.htm 2002 May 27
19. 452647 Onset and offset time-course of a methylphenidate transdermal system. Fabiano GA, Gnagy EM, Burrows-MacLean L, Hoffman MT, Pelham WE Jr Internet Site www.noven.com/research.htm 2002 May 27
20. 452649 Improved nightly parent ratings with once-daily transdermal methylphenidate. Burrows-MacLean L, Pelham WE Jr, Hoffman MT Internet Site www.noven.com/research.htm 2002 May 22
21. 452719 Ritalin side effects (from the Physicians' Desk Reference). Internet Site www.healthpoints.com/ritalin.html 2002 May 28
22. 454573 Shire Pharma Group. Good 1Q: Cautiously optimistic in transition year. Goodman M, More DC, Nachman G, Bhalla A 2002 May 02
23. 456552 Noven submits New Drug Application for once-daily MethyPatch. Noven Pharmaceuticals Inc Press Release 2002 June 27